HRPK20040528B3 - Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure - Google Patents
Use of norepinephrine reuptake inhibitors for the treatment of cognitive failureInfo
- Publication number
- HRPK20040528B3 HRPK20040528B3 HR20040528A HRP20040528A HRPK20040528B3 HR PK20040528 B3 HRPK20040528 B3 HR PK20040528B3 HR 20040528 A HR20040528 A HR 20040528A HR P20040528 A HRP20040528 A HR P20040528A HR PK20040528 B3 HRPK20040528 B3 HR PK20040528B3
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- reuptake inhibitors
- norepinephrine reuptake
- cognitive failure
- cognitive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33917401P | 2001-12-11 | 2001-12-11 | |
| PCT/US2002/036132 WO2003049724A1 (en) | 2001-12-11 | 2002-11-27 | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20040528A2 HRP20040528A2 (en) | 2004-10-31 |
| HRPK20040528B3 true HRPK20040528B3 (en) | 2006-03-31 |
Family
ID=23327833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20040528A HRPK20040528B3 (en) | 2001-12-11 | 2002-11-27 | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure |
Country Status (26)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05001705A (es) * | 2002-08-14 | 2005-04-19 | Pharmacia & Upjohn Co Llc | Uso de reboxetina para el tratamiento de sofocos. |
| WO2005011583A2 (en) * | 2003-07-28 | 2005-02-10 | Leslie Joe Dunaway | Treatment of allergic rhinitis and asthma |
| US20070105960A1 (en) * | 2003-08-27 | 2007-05-10 | Eli Lilly And Company | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors |
| KR20060121178A (ko) * | 2003-12-12 | 2006-11-28 | 일라이 릴리 앤드 캄파니 | 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제 |
| AP2006003771A0 (en) * | 2004-04-30 | 2006-10-31 | Warner Lambert Co | Substituted morpholine compounds for the treatmentof central nervous system disorders |
| US7439399B2 (en) * | 2004-06-28 | 2008-10-21 | Teva Pharmaceutical Fine Chemicals | Processes for the preparation of atomoxetine hydrochloride |
| US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
| US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
| US20100317730A1 (en) * | 2009-06-12 | 2010-12-16 | Shaya Elias K | Treatment for menopausal and perimenopausal vasomotor symptons |
| TW201107485A (en) * | 2009-07-31 | 2011-03-01 | Univ Nat Taiwan | Treating negative symptoms of schizophrenia associated with defective neuregulin 1 (NRG1) |
| US20140249180A1 (en) * | 2011-10-03 | 2014-09-04 | National Center For Geriatrics And Gerontology | Tau aggregation inhibitor |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP2962687B1 (en) | 2013-04-02 | 2019-06-05 | The Doshisha | Tau aggregation inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| US5281624A (en) * | 1991-09-27 | 1994-01-25 | Eli Lilly And Company | N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof |
| US5658590A (en) * | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| ATE305788T1 (de) * | 1999-07-01 | 2005-10-15 | Pharmacia & Upjohn Co Llc | (s,s)-reboxetin zur behandlung von inkontinenz |
| SK4732002A3 (en) * | 1999-10-13 | 2002-12-03 | Pfizer Prod Inc | Biaryl ether derivatives useful as monoamine reuptake inhibitors |
| WO2002053104A2 (en) * | 2001-01-02 | 2002-07-11 | Sention, Inc. | Use of catecholamine reuptake inhibitors to enhance memory |
| MXPA03006003A (es) * | 2001-01-02 | 2005-09-08 | Upjohn Co | Nuevas combinaciones de farmacos. |
-
2002
- 2002-11-27 JP JP2003550773A patent/JP2005517647A/ja active Pending
- 2002-11-27 US US10/496,765 patent/US20050009925A1/en not_active Abandoned
- 2002-11-27 KR KR10-2004-7009039A patent/KR20040066895A/ko not_active Withdrawn
- 2002-11-27 EP EP02789574A patent/EP1458368B1/en not_active Expired - Lifetime
- 2002-11-27 BR BR0213581-7A patent/BR0213581A/pt not_active IP Right Cessation
- 2002-11-27 HR HR20040528A patent/HRPK20040528B3/xx not_active IP Right Cessation
- 2002-11-27 AU AU2002352625A patent/AU2002352625A1/en not_active Abandoned
- 2002-11-27 DE DE60223718T patent/DE60223718T2/de not_active Expired - Fee Related
- 2002-11-27 ES ES02789574T patent/ES2295435T3/es not_active Expired - Lifetime
- 2002-11-27 CA CA002467802A patent/CA2467802A1/en not_active Abandoned
- 2002-11-27 SK SK244-2004A patent/SK2442004A3/sk not_active Application Discontinuation
- 2002-11-27 MX MXPA04005716A patent/MXPA04005716A/es not_active Application Discontinuation
- 2002-11-27 NZ NZ532065A patent/NZ532065A/en unknown
- 2002-11-27 HU HU0402619A patent/HUP0402619A3/hu unknown
- 2002-11-27 PL PL02369311A patent/PL369311A1/xx unknown
- 2002-11-27 WO PCT/US2002/036132 patent/WO2003049724A1/en not_active Ceased
- 2002-11-27 CZ CZ2004709A patent/CZ2004709A3/cs unknown
- 2002-11-27 IL IL16198902A patent/IL161989A0/xx unknown
- 2002-11-27 EA EA200400793A patent/EA200400793A1/ru unknown
- 2002-11-27 CN CNA028247264A patent/CN1713900A/zh active Pending
- 2002-12-05 MY MYPI20024591A patent/MY136367A/en unknown
- 2002-12-05 TW TW091135296A patent/TW200300672A/zh unknown
-
2004
- 2004-05-31 ZA ZA200404274A patent/ZA200404274B/en unknown
- 2004-06-09 EC EC2004005145A patent/ECSP045145A/es unknown
- 2004-06-09 CO CO04054292A patent/CO5590907A2/es not_active Application Discontinuation
- 2004-07-09 NO NO20042904A patent/NO20042904L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL369311A1 (en) | 2005-04-18 |
| NO20042904L (no) | 2004-09-07 |
| JP2005517647A (ja) | 2005-06-16 |
| AU2002352625A1 (en) | 2003-06-23 |
| ES2295435T3 (es) | 2008-04-16 |
| SK2442004A3 (en) | 2004-12-01 |
| MY136367A (en) | 2008-09-30 |
| MXPA04005716A (es) | 2004-12-06 |
| CN1713900A (zh) | 2005-12-28 |
| HUP0402619A3 (en) | 2008-04-28 |
| BR0213581A (pt) | 2004-08-24 |
| CZ2004709A3 (cs) | 2004-10-13 |
| HUP0402619A2 (hu) | 2005-03-29 |
| EP1458368B1 (en) | 2007-11-21 |
| EP1458368A1 (en) | 2004-09-22 |
| ZA200404274B (en) | 2005-09-13 |
| NZ532065A (en) | 2007-03-30 |
| US20050009925A1 (en) | 2005-01-13 |
| DE60223718D1 (de) | 2008-01-03 |
| DE60223718T2 (de) | 2008-10-30 |
| CO5590907A2 (es) | 2005-12-30 |
| KR20040066895A (ko) | 2004-07-27 |
| WO2003049724A1 (en) | 2003-06-19 |
| CA2467802A1 (en) | 2003-06-19 |
| EA200400793A1 (ru) | 2004-10-28 |
| TW200300672A (en) | 2003-06-16 |
| ECSP045145A (es) | 2004-07-23 |
| HRP20040528A2 (en) | 2004-10-31 |
| IL161989A0 (en) | 2005-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ502853A (en) | Treatment of conduct disorder with a norepinephrine reuptake inhibitor such as tomoxetine | |
| HRP20030910B1 (hr) | Tartaratne soli 5,8,14-triazatetraciklo {10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>}-heksadeka-2(11), 3,5,7,9-pentaena i pripadajućih farmaceutskih spojeva | |
| NO20063572L (no) | Kinazolinditosylatsalt forbindelser | |
| HRP20010573B1 (en) | Tricyclic inhibitors of poly(adp-ribose) polymerases | |
| ECSP045193A (es) | "nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas" | |
| CO5280078A1 (es) | Compuestos | |
| HRP20090281T1 (hr) | 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti | |
| WO2005028479A3 (en) | Hiv replication inhibiting purine derivatives | |
| MXPA02003977A (es) | Inhibidores de adhesion de celula mediada por al°2. | |
| CY1107852T1 (el) | Νεες χρησεις αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη της ημικρανιας | |
| BR0112252A (pt) | Derivados de pirazole | |
| HRP20090159T1 (en) | Use of glucosidase inhibitors for therapy of mucovisidosis | |
| BR0115936A (pt) | 2-anilino-benzimidazóis substituìdos e sua aplicação como inibidores de nhe | |
| SE0202429D0 (sv) | Novel Compounds | |
| UA83233C2 (ru) | Замещенный 2-аминотетралин для лечения депрессии | |
| UY28360A1 (es) | Nuevos compuestos | |
| DK1753723T3 (da) | Substituerede quinolinderivater som mitotiske kinesininhibitorer | |
| UY27338A1 (es) | Nuevos derivados de ácido sulfónico | |
| CO5590907A2 (es) | Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento de fallo cognitivo | |
| TR200200014T2 (tr) | Nörotik düzensizliklerin tedavisi. | |
| ATE296827T1 (de) | Heteropolycyclische inhibitoren | |
| ATE374750T1 (de) | Serotoninwiederaufnahme-inhibitoren | |
| ATE308540T1 (de) | Antithrombosemittel | |
| DK1204658T3 (da) | Benzofurylpiperazin-serotoninagonister | |
| NO20030297L (no) | Aryl sulfonamider som serotoninantagonist for behandling av fedme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AKOB | Publication of a request for the grant of a patent not including a substantive examination of a patent application (a consensual patent) | ||
| PKB1 | Consensual patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20061017 Year of fee payment: 5 |
|
| PBKO | Lapse due to non-payment of renewal fee for consensual patent |
Effective date: 20071118 |